← Leaderboards
Douglas Eric Brenneman
Kannalife Sciences, Inc.
$1,635,344
Attributed
$3,270,688
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,270,688 · 2
By mechanism
R42$2,970,772 · 1
R41$299,916 · 1
Top collaborators
- Sara J. Ward4 shared
Others in their field
Other Emerging Leaders on “Acute”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$51,003,204
- Julie Ake · National Institute Of Allergy And Infectious Diseases$41,692,120
- Xinhua Li · Nano Terra, Inc.$29,991,620
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$29,269,420
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
Research focus
AcuteCollaborationsAfferent NeuronsAnalogAnalytical MethodAffectAnti-Inflammatory AgentsAntiinflammatory EffectAttenuatedBeta-ArrestinBiological AvailabilityBiological MarkersCalciumCancer TherapyCanis FamiliarisCannabidiolCannabinoid ReceptorCannabis Sativa PlantCardiacChemotherapy-Induced Peripheral NeuropathyChronicChronic Pain ManagementClinical TrialsCytokine
Grant awards (4)
Development of KLS-13019 for Neuropathic Pain$1,001,774
R42 · FY2023 · NS · contact PI
Development of KLS-13019 for Neuropathic Pain$991,944
R42 · FY2022 · NS · contact PI
Development of KLS-13019 for Neuropathic Pain$977,054
R42 · FY2021 · NS · contact PI
Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence$299,916
R41 · FY2018 · DA